Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program
Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program. // Digestive and Liver Disease. – URL: https://www.sciencedirect.com/science/article/pii/S159086582600976X?dgcid=rss_sd_all
Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program. Digestive and Liver Disease. https://www.sciencedirect.com/science/article/pii/S159086582600976X?dgcid=rss_sd_all
“Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program.” Digestive and Liver Disease.
@article{article43320,
title = {Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program},
journal = {Digestive and Liver Disease},
url = {https://www.sciencedirect.com/science/article/pii/S159086582600976X?dgcid=rss_sd_all}
}